GlassScriptPhysician profile
Katherine Danielle Williamson
NPI 1982916375
$2,290.76
in general payments reported to CMS, 2019-2025
25 companies · $558 in 2025
The $558 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $217 · 2021: $154 · 2022: $392 · 2023: $350 · 2024: $482 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $335.70 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $237.74 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $225.45 | 2019-2025 | Bexsero, Penmenvy |
| Cognoa, INC. | $166.26 | 2022 | |
| Sanofi Pasteur INC. | $165.86 | 2019-2025 | |
| Kaleo, INC. | $148.96 | 2019-2023 | Auvi-Q |
| Adlon Therapeutics L.P. | $133.44 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $105.69 | 2024-2025 | |
| Pfizer INC. | $104.35 | 2023-2025 | |
| Tris Pharma INC | $98.59 | 2021-2024 | Quillivant, Dyanavel Xr |
| Alk-Abello, INC | $83.93 | 2025 | Neffy |
| Mirum Pharmaceuticals, INC. | $80.02 | 2025 | Cholbam |
| Ars Pharmaceuticals Operations, INC. | $73.35 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $53.01 | 2023-2024 | Qelbree, Qelbree |
| Cranial Technologies, INC | $50.01 | 2023-2025 | Doc Band |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $40.45 | 2024 | Ycanth |
| Neos Therapeutics, LP | $33.41 | 2025 | Cotempla Xr-Odt |
| Corium, LLC | $23.59 | 2022 | |
| Biomarin Pharmaceutical INC. | $23.13 | 2024 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $22.33 | 2023 | Elaprase |
| Vertical Pharmaceuticals, LLC | $21.98 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $18.92 | 2025 | Jornay Pm |
| Abbvie INC. | $15.25 | 2020 | |
| Axonics, INC. | $15.08 | 2023 | Bulkamid |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.